Global Licensing-out

한미약품에 대한 신뢰와 사랑을 언제나 보내주시는 고객 여러분께 깊은 감사의 말씀을 드립니다.

Hanmi Pharm. is dedicated to developing and providing innovative, valuable drugs to its customers. In order to pursue this goal, Hanmi is highly interested in collaborative opportunities including product in and out-licensing, co-research, co-development, co-promotion, and co-marketing with research institutes, pharmaceutical companies, and biotech companies domestically and internationally.

Platform Technology & NCEs

Collaboration Model
  • Licensing of Pipeline Products
  • Early Stage Collaboration of Pipeline Products
  • Research Collaboration for application of Hanmi's Platform Technology
Partnering Strategy
  • Partnering Stage: Lead Optimization/Preclinical ~ Point of POC
  • Partnering Territory: Worldwide or Regional
  • Partnering Company: Big Pharma or Biotech
Key Assets
  • LAPSCOVERY (Long Acting Biologics) Platform Technology & Pipeline
  • Early Stage Collaboration of Pipeline Products

Fixed Dose Combinations(FDC)

Collaboration Model
  • Co-development & co-marketing/co-promotion/royalty base
  • Supply of finished product
Partnering Strategy
  • Discussion steps
    1. Understanding Hanmi's capability & pipeline
    2. Understanding partner's needs and capabilities
    3. Agreeing on mutual interest
    4. Establishing a specific collaboration model
  • Ideal partner
    1. Companies with global presence in need of life cycle management
    2. R&D-based companies

Value Added Generics(VAG)

Collaboration Model
  • License-out VAG/generics to enhance Hanmi’s presence and competitive edge in target markets.
  • Technology transfer in markets where local manufacturing is more efficient or required.
  • For partners in need of high quality API/intermediates at competitive prices
Partnering Strategy
  • Collaborate with top pharmaceutical players in local and regional markets available to promote, market and distribute Hanmi products.
  • Promote Hanmi products to maintain the highest level of customer satisfaction